- Company
- Eisai strengthened Pariet's sales, collaborated with Yuhan
- by Nov 6, 2020 06:25am
- Eisai strengthened the collaboration of Pariet (Rabeprazole) with a domestic company of PPI. The joint sales were expanded to Pariet 10·20mg following low-dose Pariet 5mg. According to the pharmaceutical industry on the 3rd, Yuhan recently signed a joint sale contract with Eisai for Pariet 10·20mg, and started supplying the product fro
- Company
- Lilly implements ERP for the sales department
- by Nov 5, 2020 11:03am
- On the 4th, Lilly Korea announced the implementation of ERP to all employees of the sales department. It is known that the ERP compensation condition adds 8 months to twice the number of years of service, and provides annual consolation money. Although the exact size is undecided, it is intended for all employees of the sales organizati
- Company
- Zuellig Pharma union reports company’s abusive practice
- by An, Kyung-Jin Nov 5, 2020 06:41am
- The management and labor union dispute in Zuellig Pharma Korea’s subsidiary Zuellig Pharma Solutions Service Korea seems to be intensifying fast. According to the pharmaceutical industry sources on Nov. 3, Korea Democratic Pharmaceutical Union has recently reported Zuellig Pharma Solutions Service Korea management for their unfair lab
- Company
- Gilead, registered 6 patents for Remdesivir in Korea
- by Kim, Jin-Gu Nov 5, 2020 06:40am
- It is confirmed that Gilead recently registered a patent related to Remdesivir (Veklury) in Korea. Remdesivir is currently the only drug approved for the treatment of COVID-19. In Korea, it was supplied in earnest from last July. According to the MFDS and the KIPO on the 3rd, Gilead registered six patents related to Remdesivir in the dome
- Company
- MSD Korea appoints Seongpil Kim as executive director
- by Nov 5, 2020 06:40am
- MSD Korea (CEO Kevin Peters) announced on the 1st that it had appointed Kim Seong-pil (43 years old), executive director of the anticancer drug division. In December 2018, the new executive director of Seongpil Kim joined MSD Korea as the 'Commercial Operations Lead', which led to double-digit growth. He has also contributed significan
- Company
- Multinational companies rush to appoint new CEOs
- by Eo, Yun-Ho Nov 5, 2020 06:40am
- Multiple Korean subsidiaries of multinational pharmaceutical companies are reporting their news of newly appointed top executives. Just in the latter half of the year, six companies have welcomed their new leaders. According to pharmaceutical industry sources, Sanofi Pasteur Korea, Galderma Korea, Ono Pharma Korea, MSD Korea, Organ
- Company
- Soliris competitor Roche’s Enspryng readies for South Korea
- by Eo, Yun-Ho Nov 4, 2020 06:09am
- Apparently, Enspryng, a Soliris (eculizumab) competitor, is making a move to enter the South Korean market. The pharmaceutical industry sources reported Roche Korea has recently submitted an approval application on a neuromyelitis optica spectrum disorder (NMOSD) treatment Enspryng (satralizumab) to the Ministry of Food and Drug Safety (
- Policy
- The HIRA is conducting RWE research on cancer & rare dz
- by Lee, Hye-Kyung Nov 4, 2020 06:09am
- The HIRA will be conducting prospective clinical research to secure real world evidence (RWE) for cancer and rare disease treatments in earnest starting next month. From last year to recently, the RWE guidelines were created through retrospective studies, and from this year to 2023,'prospective clinical research to prepare a platform for
- Policy
- New reimbursement standards on Rinvoq and Remicade
- by Kim, Jung-Ju Nov 4, 2020 06:09am
- Starting this month, the drug reimbursement would be granted on AbbVie Korea's rheumatoid arthritis treatment Rinvoq Sustained-release Tablet (upadacitinib) 15mg. As a result, the reimbursement standards have been changed for drugs with other various substances available for a treatment switch, and the combination therapy with the drug would
- Policy
- Hanmi’s generic for Nexavar has been approved
- by Lee, Tak-Sun Nov 4, 2020 06:08am
- Hanmi's generic for Nexavar (Sorafenib, Bayer) was first approved in the liver cancer treatment market. In addition, it acquired exclusive rights in the generic market for nine months after its launch. On the 29th, the MFDS approved Hanmi's Soranib 200mg. Soranib is generic for Nexavar. It is used for hepatocellular carcinoma, advanced
